Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple-Dose, Dose-Escalation, Randomized, Double-Blind, Placebo-Controlled Phase Ⅱa Clinical Trial to Evaluate the Safety, Pharmacokinetic (PK) Profile and Preliminary Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency

NCT07551804 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.

NCT NCT07551804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07551804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple-Dose, Dose-Escalation, Randomized, Double-Blind, Placebo-Controlled Phase Ⅱa Clinical Trial to Evaluate the Safety, Pharmacokinetic (PK) Profile and Preliminary Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
Lead sponsor
Xiamen Amoytop Biotech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
June 10, 2026
Completion date
June 30, 2028
Enrollment
36 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adult growth hormone deficiency